Navigation Links
China Pharma Holdings, Inc. CEO to Speak at Brean Murray, Carret & Co. 2010 Life Sciences Summit

HAIKOU CITY, China, May 13 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ("China Pharma" or the "Company"), a leading fully-integrated specialty pharmaceuticals company in China, today announced that the Company's Chief Executive Officer and President, Ms. Zhilin Li, has been invited to be a speaker on a panel at the Brean Murray, Carret & Co. (BMC) 2010 Life Sciences Summit.

Brean Murray, Carret & Co. 2010 Life Sciences Summit will be held on Monday, May 17, 2010 at the Grand Hyatt Hotel in New York City. Ms. Li is scheduled to be one of five speakers on the "Winners and Losers of China Healthcare Reform" panel at 2:00 pm ET. The discussion will highlight the unprecedented $124 billion healthcare reform in China, and the opportunities for and potential impact on a range of participants in the healthcare industry.

Ms. Li will be available to meet with institutional investors throughout the conference. For further details, please contact your respective institutional sales representative.

"I am honored to be invited as a panel speaker at BMC's 2010 Life Sciences Summit to discuss China's healthcare reform with industrial professionals, entrepreneurs and the investment community," said Ms. Zhilin Li, CEO and president of China Pharma, "I look forward to having an in-depth discussion with other industry experts on incremental government healthcare reform expenditure, essential drug list (EDL) and medical insurance, and corresponding strategies to capitalize on these new opportunities. We expect the impact of the reform to be significant to the pharmaceutical industry in the coming years. We will remain nimble to enhance our execution strategy as needed in response to the new environment when it becomes a reality."

As a founder of Hainan Helpson Medical & Biotechnology Co., Ltd., (a wholly owned subsidiary of CPHI), Ms. Li has demonstrated in-depth knowledge of the Chinese pharmaceutical market, and distinguished capabilities to design and execute strategies during the past 17 years of leading the Company.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a rapidly growing specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across 30 provinces, municipalities and autonomous regions. The Company's wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit .

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

    For more information, please contact:

     China Pharma Holdings, Inc.
     Phone: +86-898-6681-1730 (China)

    CCG Investor Relations
     Lei Huang, Account Manager
     Phone: +1-646-833-3417 (New York)

     Vivian Chen, Sr. Market Intelligence Exec.
     Phone: +1-646-701-7445(New York)

SOURCE China Pharma Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Sky One Medical Provides Sales Forecast for 13 New Products
2. China Sky One Medical Attended Import and Export Fair to Enhance International Growth Opportunity
3. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
4. China Pharma Holdings, Inc. Reports First Quarter 2010 Financial Results
5. China Sky One Medical Announces Preliminary First Quarter 2010 Results; Reschedules Earnings Conference Call
6. China Medicine Announces Conference Call to Discuss First Quarter 2010 Results
7. China Sky One Medical Announces Conference Call to Discuss First Quarter 2010 Results
8. Reportlinker Adds Future of Red Biotechnology in China
9. Chinas first open-access journal Nano Research listed in Science Citation Index
10. Australia Substantially Increases Research Collaboration with China, According to Thomson Reuters Study
11. China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010
Post Your Comments:
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... 2016 Andrew D ... Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology:
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
Breaking Biology News(10 mins):